000963 Huadong Medicine
- 36.30
- +1.33+3.80%
Huadong Medicine News
Huadong Pharmaceutical: Announcement on the achievements of the 2022 Restricted Stock Incentive Plan to grant restricted stocks for the first time during the second period of lifting the sales restrictions and lifting the sales restrictions
Huadong Pharmaceutical: Supervisory Board\'s inspection opinions on the Company\'s 2022 Restricted Stock Incentive Plan granted restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
East China Pharmaceutical: Announcement of Resolutions of the 20th Meeting of the 10th Board of Supervisors
Huadong Pharmaceutical: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on Huadong Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan grants restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
Huadong Pharmaceutical: Announcement of Resolutions of the 30th Meeting of the 10th Board of Directors
Huadong Pharmaceutical: Announcement on Adjusting the Repurchase Price of the 2022 Restricted Stock Incentive Plan
Huadong Pharmaceutical: Legal Opinion of Zhejiang Tianze Law Firm on Huadong Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan grants restricted shares for the first time, the achievements of lifting sales restrictions during the second period of lifting restrictions, adjusting the repurchase price of restricted stocks, and the repurchase and cancellation of some restricted stocks
Huadong Pharmaceutical: Announcement on Proposed Repurchase and Cancellation of Some Restricted Shares
Huadong Pharmaceutical: Report for the Third Quarter of 2024 (English Version)
Huadong Pharmaceutical: Announcement on the holding subsidiary obtaining a notice of approval for drug clinical trials
Huadong Pharmaceutical: Announcement on Wholly-owned Subsidiaries Obtaining US FDA Clinical Trial Approval Notice for New Drugs
Huadong Pharmaceutical: Notice on Wholly Owned Subsidiaries Obtaining Drug Registration Certificates
Huadong Pharmaceutical: Investor Relations Activity Record Form for October 25, 2024
Huadong Pharmaceutical: Announcement of Resolutions of the 29th Meeting of the 10th Board of Directors
Huadong Pharmaceutical: Report for the third quarter of 2024
East China Pharmaceutical: Announcement of Resolutions of the 19th Meeting of the 10th Board of Supervisors
Huadong Pharmaceutical: An indicative announcement on the 2022 Restricted Stock Incentive Plan to reserve and grant restricted shares for the first time to lift the sales restriction period and release the listing and circulation of restricted shares
Huadong Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining a Notice of Approval for Drug Clinical Trials
Huadong Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining a Notice of Approval for Drug Clinical Trials
Huadong Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining a Notice of Approval for Drug Clinical Trials
Analysis
Price Target
No Data
No Data